Heparin Market

• Market at over $3 billion for injectable form and growing ~ 15% annually

  • Wall Street estimate of peak sales for Exanta was $4 billion

• Used to prevent and treat blood clots

• Oral form would expand the market for heparin

• FDA advisory panel rejection of Astra Zeneca’s oral Exanta underscores need for a safe and effective oral anti-coagulant

Previous slide

Next slide

Back to first slide

View graphic version